tldrdailynews.com logo

Novo Nordisk's Wegovy Gains US Approval for MASH Treatment

1 min read
Source: Reuters
Novo Nordisk's Wegovy Gains US Approval for MASH Treatment
Photo: Reuters
TL;DR

Novo Nordisk's Wegovy has received accelerated FDA approval to treat MASH, making it the first GLP-1 therapy approved for this liver condition, based on promising early trial results, with plans for approval in Europe and Japan.

Topics:businesshealth#fda-approval#health#mash#metabolic-disease#novo-nordisk#wegovy
Share this article
  1. Novo Nordisk's Wegovy gets accelerated US approval for liver disease MASH  Reuters
  2. Novo Nordisk’s Wegovy Gets US Approval for Liver Disease  Bloomberg.com
  3. Novo Nordisk’s obesity drug Wegovy cleared to treat MASH  statnews.com
  4. Wegovy® approved by FDA for the treatment of adults with noncirrhotic MASH with moderate to advanced liver fibrosis  PR Newswire
  5. Novo Nordisk A/S: Wegovy® approved in the US for the treatment of MASH  Yahoo Finance

Want the full story? Read the original reporting

Read on Reuters